Radio and PodcastLive Radio & PodcastsOpening Radio and Podcast...
Radio and PodcastLive Radio & PodcastsFetching podcast shows and categories...
Radio and PodcastLive Radio & PodcastsFetching podcast episodes...
Oncology Pharmacist & Educator. Talking all things #oncopharm
This is our 1st in a series of podcasts/videos to role out once or twice a year on therapeutic targets in cancer. First up - Trop2 Check out...
This week we highlight some promising clinical research in the pancreatic cancer space. Daraxonrasib has shown OS benefit vs. chemo in the 2...
Bibliography: 1.. 2019 Systematic Review of Published Cases: https://doi.org/10.1111/dme.14050 2. Mass General Data & Publication: https://j...
Discussing the new nab-paclitaxel adjunctive medication, relacorilant, for ovarian cancer. As a glucoCORticoid receptor antagonist, it is ha...
Recapping what I learned at HOPA 2026: -Beyond steroids for irAs -IT chemo beyond methotrexate and cytarabine -Pre-emptive CMV management in...
Nivolumab-AVD is finally approved for Hodgkin Lymphoma, and primary G-CSF prophylaxis is recommended (?) in the PI. Also, brief NOLA preview...
Tazemetostat is withdrawn from the market due to a risk of secondary malignancies. RECITE asks if romiplostim improves platelet counts for p...
Lots of FDA approval updates to discuss from the past few weeks: -Zongertinib gets approved in 1st line setting for ERBB2 TKD mutated metast...
This week discuss BR.31 trial of adjuvant durvalumab in NSCLC and put it into the context of the positive studies with atezolizumab and pemb...
An exciting new drug, rezatapopt, may be effective in restoring p53 activity in cancers - a possible major therapeutic breakthrough. Can col...
The EV-303 trial that led to the FDA approval of perioperative enfortumab vedotin + pembrolizumab in cisplatin-ineligible bladder cancer pat...
We have FDA changes to the labels of Axi-Cel (to allow for its use in primary CNS lymphoma) and 5-flourouracil (pre-treatment DPYD testing)....
A brief discussion of the Core Communication Skills* and how to incorporate them into a chemotherapy education session. *Rapport Building *A...
Reviewing the hot-off-the press publication of PATINA, palbociclib in HER-2 amplified breast cancer along with endocrine therapy and HER-2 t...
We review the recent ASCENT-04/Keynote-D19 publication of sacituzuab govitecan + pembrolizumab for PD-L1 CPS of 10% and above TNBC compared...
This episode is the 2nd chapter in a broader presentation about putting together the puzzle pieces of oncology drug use. This chapter discus...
A Holiday tradition like few other. Are we keeping, regifting, or returning new oncology drugs approved in 2025?
Are we nearing the end of the Platinum Era in bladder cancer? A press release suggests enfortumab vedotin + pembrolizumab in a perioperative...
ASH 2025 Highlights: MajesTEC-3: Teclistamab + Daratumumab in relapse refractory Multiple Myeloma Paradigm: HMA + Ven vs. 7+3 or CPX-351 Den...
DPYD testing is more complicated than one would think! We talk through the steps to consider when initiating DPYD testing at your site. Reso...
We are back with lots of OncoPharm updates: 1. The belantamab mafodotin REMS program details are available....and it's a lot. How will belan...
Our 3rd and final installment in this Oncology Pharmacy Training Pathways mini-series discusses the PGYNone route. I am joined by Vineetha T...
Our 2nd installment in this Oncology Pharmacy Training Pathways mini-series discusses the PGY1 pharmacy residency route, without a PGY2 onco...
Our 1st installment in this Oncology Pharmacy Training Pathways mini-series discusses the PGY2 oncology pharmacy residency rout. I am joined...
[Moving Trailer Voice] This Halloween: They always come back.... The latest revival is belantamab mafodotin, FDA approved...again. After bei...
This week's episode recaps some highlights from ESMO 2025: 1. Destiny-Breast05: T-DXd > T-DM1 in persistent HER2+ disease after neoadjuvant...
IL-2, one of the founding fathers of our current immunotherapy landscape, is discussed.
Maintenance therapy with ICIs (atezolizumab or durvalumab) is already established in extensive stage small-cell lung cancer, but lurbinected...
Our Landmarks of OncoPharm series returns to discuss PARAMOUNT, a landmark study that helped solidify the role of maintenance pemetrexed in...
The long awaited subcutaneous formulation of pembrolizumab is not FDA-approved. We discuss its administration and toxicity & PK differences...
We discuss the ALASCCA study (Adjuvant Low-doseASpirin in Colorectal CAncer
The 2025 World Conference on Lung Cancer just concluded, and there are several notable updates concerning treatment of EGFR-mutated NSCLC. 1...
The 5-year+ follow-up from CARTITUDE-1 has people asking if cilta-cel can cure multiple myeloma? We discuss this data and the broad comparis...
The potential breakthrough in RNA vaccine technology has been increasingly discussed on social media. This episode looks at one promising st...
Malignant Hematology Updates: Venetoclax dosing strategies continue to evolve HMA/Ven + IDH1/2 inhibitors: https://doi.org/10.1200/JCO-25-00...
A new ERBB2 (HER2) targeting TKI is approved for NSCLC. We review the characteristics of the drug and summarize the current landscape in tre...
This week's episode discusses the first-in-class agent, dordaviprone and a randomized control trial that demonstrated an oncology pharmacist...
More isn't always better. Our Landkmarks of OncoPharm series covers lessons learned from the ProMACE-CytaBOM regimen for NHL. ProMACE-CytaBO...
A brief overview of testicular cancer
A few supportive care updates: 1. Skin prophylaxis to prevent severe dermatologic toxicity with Nivo/Ipi. Note* published in JCO Oncology Pr...
Two new drug approvals to talk about (after I misplaced my notes!)
Antiandrogen withdrawal is an historically well described phenomenon where prostate cancer patients experience PSA responses AFTER stopping...
A plethora of recent updates: -Pembrolizumab (perioperative) in head & neck cancer (Keynote-689) -Prostate cancer updates on cabozantinib/at...
A recap of notable updates from ASCO 2025 1. Destiny-Breast09 2. BREAKWATER 3. ATOMIC 4. Delphi-304 5. CM 816 OS update 6. C-POST 7. Matterh...
Our Landmarks of OncoPharm series returns to discuss the CLEOPATRA study, which established docetaxel, trastuzumab, pertuzumab (THP) as a st...
If you've been struggling with how to talk to patients about ivermectin for cancer, then this podcast is for you. 1. Cancer misinformation o...
Discussing recent FDA approvals of penpulimab, avutometenib, defactinib, and telisotuzumab vedotin.
A splashy large study and two small studies suggest IV Mg in pre-hydration fluids can decrease the risk of cisplatin kidney injury. Gupta et...
This episode summarizes recent updates on: Tumor infiltrating clonal hematopoiesis (TI-CH) and its apparent negative impact on solid tumors...
BRCA revision mutations may explain some of the limited benefit seen in long-term follow-up studies with PARP inhibitors. Bibliography: 1: B...